(Q38083427)

28 August 2017

title

Multidrug therapy for polycystic kidney disease: a review and perspective (English)

1 reference

polycystic kidney disease

28 August 2017

main subject

1 reference

Gianluca Aguiari

1

1 reference

28 August 2017

Luigi Catizone

series ordinal

2

1 reference

28 August 2017

Laura Del Senno

series ordinal

3

1 reference

28 August 2017

language of work or name

1 reference

15 February 2013

1 reference

American Journal of Nephrology

28 August 2017

published in

1 reference

28 August 2017

volume

37

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

175-182

1 reference

Epidermal growth factor-mediated proliferation and sodium transport in normal and PKD epithelial cells

28 August 2017

cites work

1 reference

Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells

21 January 2018

1 reference

The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease

21 January 2018

1 reference

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease

21 January 2018

1 reference

Sirolimus and kidney growth in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

Everolimus in patients with autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents

21 January 2018

1 reference

Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells

21 January 2018

1 reference

Bending the MDCK cell primary cilium increases intracellular calcium

21 January 2018

1 reference

Polycystin-2 and phosphodiesterase 4C are components of a ciliary A-kinase anchoring protein complex that is disrupted in cystic kidney diseases

21 January 2018

1 reference

Novel role for polycystin-1 in modulating cell proliferation through calcium oscillations in kidney cells

21 January 2018

1 reference

Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys

21 January 2018

1 reference

Fluid transport and cystogenesis in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease--a contiguous gene syndrome

21 January 2018

1 reference

Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR

21 January 2018

1 reference

Regulation of mTOR by polycystin-1: is polycystic kidney disease a case of futile repair?

21 January 2018

1 reference

Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1.

21 January 2018

1 reference

A plethora of epidermal growth factor-like proteins in polycystic kidneys

21 January 2018

1 reference

Polycystin-1 regulates amphiregulin expression through CREB and AP1 signalling: implications in ADPKD cell proliferation.

21 January 2018

1 reference

Inhibition of HER-2(neu/ErbB2) restores normal function and structure to polycystic kidney disease (PKD) epithelia

21 January 2018

1 reference

Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin

21 January 2018

1 reference

Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.

21 January 2018

1 reference

Somatostatin analog therapy for severe polycystic liver disease: results after 2 years

21 January 2018

1 reference

Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide

21 January 2018

1 reference

Deficiency of polycystic kidney disease-1 gene (PKD1) expression increases A(3) adenosine receptors in human renal cells: implications for cAMP-dependent signalling and proliferation of PKD1-mutated cystic cells

21 January 2018

1 reference

Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells

21 January 2018

1 reference

Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1.

21 January 2018

1 reference

Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).

21 January 2018

1 reference

Sirolimus therapy to halt the progression of ADPKD.

21 January 2018

1 reference

mTOR inhibitors and autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats

21 January 2018

1 reference

Curcumin inhibits renal cyst formation and enlargement in vitro by regulating intracellular signaling pathways

21 January 2018

1 reference

Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model.

21 January 2018

1 reference

c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation

21 January 2018

1 reference

Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease

21 January 2018

1 reference

Triptolide reduces cystogenesis in a model of ADPKD.

21 January 2018

1 reference

Clinical effects of calcium channel blockers and renin-angiotensin-aldosterone system inhibitors on changes in the estimated glomerular filtration rate in patients with polycystic kidney disease.

21 January 2018

1 reference

Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease

21 January 2018

1 reference

Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects.

21 January 2018

1 reference

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.

21 January 2018

1 reference

Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer

21 January 2018

1 reference

Differential mTOR and ERK pathway utilization by effector CD4 T cells suggests combinatorial drug therapy of arthritis

21 January 2018

1 reference

c-Src associates with ErbB2 through an interaction between catalytic domains and confers enhanced transforming potential

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000346812

1 reference

28 August 2017

1 reference